

## REMARKS

Claims 1-35 are pending in this application. Claims 10-13, 16-20, 23, 25-28, 31, 32, 34 and 35 stand rejected. Claims 14, 15, 21, 22, 24, 29, 30 and 33 are objected to as being dependent upon a rejected base claim.

### **Allowable Subject Matter**

Claims 14, 15, 21, 22, 24, 29, 30 and 33 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claim 10 has been amended to incorporate the allowable subject matter of Claim 21.

Claim 14 has been amended into independent form including all the limitations of the base claim and any intervening claims.

Claim 15 has been amended into independent form including all the limitations of the base claim.

Claim 21 has been cancelled.

Claim 22 has been amended into independent form including all the limitations of the base claim.

Claim 23 has been amended to incorporate the allowable subject matter of Claim 30.

Claims 24 has been amended into independent form including all the limitations of the base claim.

Claim 29 has been amended into independent form including all the limitations of the base claim and any intervening claims.

Claim 33 has been amended into independent form including all the limitations of the base claim and any intervening claims.

Claim 35 has been cancelled.

### **35 USC § 102**

Claims 10, 11, 13, 16, 23, 25, 31, 32 and 35 are rejected under 35 U.S.C. 102(b) as being anticipated by Ebinuma et al. (US 5,150,391). The claims as amended render the rejection moot.

Ebinuma does not teach the predetermined threshold in the range between 1 and 5 MeV or greater than 3MeV are recited in Independent Claims 10 and 23. As Claims 11, 13, 16, 25, 31, and 32 depend from Claims 10 and 23 respectively, they are also allowable over the cited art irrespective of the additional patentable subject matter recited therein.

**35 USC § 103**

Claims 12, 17, 18, 20, 26- 28 and 34 are rejected under 35 U.S.C. 102(b) as being unpatentable over Ebinuma et al. (US 5,150,391), in view of Flanders et al. (US 4,254,174). The Claims as amended render the rejection moot.

The addition of Wagner does not obviate the deficiencies of Ebinuma and Flanders with respect to Claims 10 and 23 from which they depend, therefore the rejection is improper and must be withdrawn.


Claim 19 is rejected under 35 U.S.C. 102(b) as being unpatentable over Ebinuma et al. (US 5,150,391), in view of Flanders et al. (US 4,254,174), further in view of Wagner (US 4,548,883). The Claims as rejected render the rejection moot.

The addition of Wagner does not obviate the deficiencies of Ebinuma and Flanders with respect to Claim 10 from which Claim 19 depends, therefore the rejection is improper and must be withdrawn.

If the Examiner has any questions relating to this response or the application in general she is respectfully requested to contact the undersigned so that prosecution may be expedited.

If necessary to effect a timely response, this paper should be considered as a petition for an Extension of Time sufficient to effect a timely response, and please charge any deficiency in fees or credit any overpayments to Deposit Account No. **04-1679** (Docket N1280-00225)

Respectfully submitted,



---

Patrick Craig Muldoon Reg. No. 47,343

DUANE MORRIS LLP  
1667 K Street, N.W., Suite 700  
Washington, D.C. 20006  
Telephone: (202) 776-7800  
Facsimile : (202) 776-7801

Dated: June 29, 2006